{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:34:41Z","timestamp":1792704881472,"version":"4.5.0"},"reference-count":360,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Autoimmune Bullous Diseases (AIBDs), characterized by the formation of blisters due to autoantibodies targeting structural proteins, pose significant therapeutic challenges. Current treatments, often involving glucocorticoids or traditional immunosuppressants, are limited by their non-specificity and side effects. Cytokines play a pivotal role in AIBDs pathogenesis by driving inflammation and immune responses. The JAK-STAT pathway is central to the biological effects of various type I and II cytokines, making it an attractive therapeutic target. Preliminary reports suggest that JAK inhibitors may be a promising approach in PV and BP, but further clinical validation is required. In AIBDs, particularly bullous pemphigoid (BP) and pemphigus vulgaris (PV), JAK inhibitors have shown promise in modulating pathogenic cytokine signaling. However, the safety and selectivity of JAK inhibitors remain critical considerations, with the potential for adverse effects and the need for tailored treatment strategies. This review explores the role of cytokines and the JAK-STAT pathway in BP and PV, evaluating the therapeutic potential and challenges associated with JAK inhibitors in managing these complex disorders.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1563286","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T02:03:57Z","timestamp":1744077837000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["JAK-STAT pathway, type I\/II cytokines, and new potential therapeutic strategy for autoimmune bullous diseases: update on pemphigus vulgaris and bullous pemphigoid"],"prefix":"10.3389","volume":"16","author":[{"given":"Xiaoying","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifang","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingwang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.15046","article-title":"Autoimmune bullous dermatoses","volume":"21","author":"Holtsche","year":"2023","journal-title":"J Der Deutschen Dermatologischen Gesellschaft = J German Soc Dermatology: JDDG"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.2018.16.issue-11","article-title":"Bullous autoimmune dermatoses","volume":"16","author":"Hofmann","year":"2018","journal-title":"J Der Deutschen Dermatologischen Gesellschaft = J German Soc Dermatology: JDDG"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.01.047","article-title":"Diagnosis and classification of autoimmune blistering diseases","volume":"13","author":"Baum","year":"2014","journal-title":"Autoimmun Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31778-7","article-title":"Pemphigus","volume":"394","author":"Schmidt","year":"2019","journal-title":"Lancet (London England)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"17026","DOI":"10.1038\/nrdp.2017.26","article-title":"Pemphigus","volume":"3","author":"Kasperkiewicz","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-017-8662-z","article-title":"Pemphigus: a comprehensive review on pathogenesis, clinical presentation and novel therapeutic approaches","volume":"54","author":"Pollmann","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.11.014","article-title":"Laminin \u03b24 is a constituent of the cutaneous basement membrane zone and additional autoantigen of anti-p200 pemphigoid","volume":"90","author":"Goletz S","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases","volume":"2013","author":"Schmidt","year":"9863","journal-title":"Lancet (London England)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-200110000-00006","article-title":"Side effects of corticosteroid therapy","volume":"33","author":"Buchman","year":"2001","journal-title":"J Clin Gastroenterol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2611","article-title":"Mortality and cause of death in patients with pemphigus","volume":"97","author":"Kridin","year":"2017","journal-title":"Acta dermato-venereologica"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0976-5","article-title":"Targeted therapies for autoimmune bullous diseases: current status","volume":"78","author":"Amber","year":"2018","journal-title":"Drugs"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2023.2242778","article-title":"Autoimmune blistering diseases: promising agents in clinical trials","volume":"32","author":"Olbrich","year":"2023","journal-title":"Expert Opin On Investigational Drugs"},{"key":"B13","doi-asserted-by":"publisher","first-page":"100004","DOI":"10.1016\/j.xjidi.2021.100004","article-title":"Epidemiology of pemphigus","volume":"1","author":"Kridin","year":"2021","journal-title":"JID Innov"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2012.2994","article-title":"Mortality of bullous pemphigoid in China","volume":"149","author":"Li","year":"2013","journal-title":"JAMA Dermatol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","article-title":"Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases","volume":"12","author":"Schwartz","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discovery"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3691","article-title":"Mechanisms and consequences of Jak-STAT signaling in the immune system","volume":"18","author":"Villarino","year":"2017","journal-title":"Nat Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-022-00537-3","article-title":"STAT proteins in cancer: orchestration of metabolism","volume":"23","author":"Li","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/gb-2004-5-12-253","article-title":"The janus kinases (Jaks)","volume":"5","author":"Yamaoka","year":"2004","journal-title":"Genome Biol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nrm909","article-title":"Stats: transcriptional control and biological impact","volume":"3","author":"Levy","year":"2002","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: impact on human disease and therapeutic intervention","volume":"66","author":"O\u2019Shea","year":"2015","journal-title":"Annu Rev Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-021-00726-8","article-title":"Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach","volume":"18","author":"Tanaka","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.04.052","article-title":"SnapShot: jak-STAT signaling II","volume":"181","author":"Villarino","year":"2020","journal-title":"Cell"},{"key":"B24","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1186\/s12864-019-6033-2","article-title":"Evidence for a non-canonical JAK\/STAT signaling pathway in the synthesis of the brain\u2019s major ion channels and neurotransmitter receptors","volume":"20","author":"Hixson","year":"2019","journal-title":"BMC Genomics"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcb.2008.08.008","article-title":"Canonical and non-canonical JAK-STAT signaling","volume":"18","author":"Li","year":"2008","journal-title":"Trends Cell Biol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.323899","article-title":"Mechanisms of unphosphorylated STAT3 transcription factor binding to DNA","volume":"287","author":"Timofeeva","year":"2012","journal-title":"J Biol Chem"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3278","article-title":"The phosphatase DUSP2 controls the activity of the transcription activator STAT3 and regulates TH17 differentiation","volume":"16","author":"Lu","year":"2015","journal-title":"Nat Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e28087","DOI":"10.4161\/jkst.28087","article-title":"Protein tyrosine phosphatases as wardens of STAT signaling","volume":"3","author":"B\u00f6hmer","year":"2014","journal-title":"JAKSTAT"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/nri1226","article-title":"Regulation of JAK-STAT signalling in the immune system","volume":"3","author":"Shuai","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/nri2093","article-title":"SOCS proteins, cytokine signalling and immune regulation","volume":"7","author":"Yoshimura","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1038\/s41467-018-04013-1","article-title":"The molecular basis of JAK\/STAT inhibition by SOCS1","volume":"9","author":"Liau","year":"2018","journal-title":"Nat Commun"},{"key":"B32","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.tips.2019.03.001","article-title":"Targeting SOCS proteins to control JAK-STAT signalling in disease","volume":"40","author":"Durham","year":"2019","journal-title":"Trends Pharmacol Sci"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02392","article-title":"Protein inhibitor of activated STAT (PIAS) negatively regulates the JAK\/STAT pathway by inhibiting STAT phosphorylation and translocation","volume":"9","author":"Niu","year":"2018","journal-title":"Front Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/sj.cr.7310027","article-title":"Regulation of cytokine signaling pathways by PIAS proteins","volume":"16","author":"Shuai","year":"2006","journal-title":"Cell Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"3460","DOI":"10.1038\/nri1667","article-title":"Regulation of gene-activation pathways by PIAS proteins in the immune system","volume":"5","author":"Shuai","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/383726a0","article-title":"Functional interactions between Stat5 and the glucocorticoid receptor","volume":"383","author":"St\u00f6cklin","year":"1996","journal-title":"Nature"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/377065a0","article-title":"Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)","volume":"377","author":"Macchi","year":"1995","journal-title":"Nature"},{"key":"B38","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1126\/science.270.5237.797","article-title":"Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development","volume":"270","author":"Russell","year":"1995","journal-title":"Sci (New York N.Y.)"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2006.09.009","article-title":"Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity","volume":"25","author":"Minegishi","year":"2006","journal-title":"Immunity"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-679902","article-title":"Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype","volume":"127","author":"Toubiana","year":"2016","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa073687","article-title":"STAT3 mutations in the hyper-IgE syndrome","volume":"357","author":"Holland","year":"2007","journal-title":"New Engl J Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1126\/science.181845","article-title":"Selective in vitro growth of T lymphocytes from normal human bone marrows","volume":"193","author":"Morgan","year":"1976","journal-title":"Sci (New York N.Y.)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1126\/science.7973659","article-title":"Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits","volume":"266","author":"Miyazaki","year":"1994","journal-title":"Sci (New York N.Y.)"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/1074-7613(95)90141-8","article-title":"The role of shared receptor motifs and common Stat proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15","volume":"2","author":"Lin","year":"1995","journal-title":"Immunity"},{"key":"B45","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.immuni.2013.01.004","article-title":"Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy","volume":"38","author":"Liao","year":"2013","journal-title":"Immunity"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/312641a0","article-title":"Human interleukin-2 promotes proliferation of activated B cells via surface receptors similar to those of activated T cells","volume":"312","author":"Mingari","year":"1984","journal-title":"Nature"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1126\/science.3116668","article-title":"The IL-2 receptor beta chain (p70): role in mediating signals for LAK, NK, and proliferative activities","volume":"238","author":"Siegel","year":"1987","journal-title":"Sci (New York N.Y.)"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(02)00367-9","article-title":"CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2","volume":"17","author":"Malek","year":"2002","journal-title":"Immunity"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/353858a0","article-title":"Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis","volume":"353","author":"Lenardo","year":"1991","journal-title":"Nature"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2030","article-title":"Modulation of cytokine receptors by IL-2 broadly regulates differentiation into helper T cell lineages","volume":"12","author":"Liao","year":"2011","journal-title":"Nat Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1656","article-title":"Priming for T helper type 2 differentiation by interleukin 2-mediated induction of interleukin 4 receptor alpha-chain expression","volume":"9","author":"Liao","year":"2008","journal-title":"Nat Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1301138111","article-title":"Opposing actions of IL-2 and IL-21 on Th9 differentiation correlate with their differential regulation of BCL6 expression","volume":"111","author":"Liao","year":"2014","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2007.02.009","article-title":"Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation","volume":"26","author":"Laurence","year":"2007","journal-title":"Immunity"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2012.02.012","article-title":"Interleukin-2 inhibits germinal center formation by limiting T follicular helper cell differentiation","volume":"36","author":"Ballesteros-Tato","year":"2012","journal-title":"Immunity"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1084\/jem.155.3.914","article-title":"Identification of a T cell-derived b cell growth factor distinct from interleukin 2","volume":"155","author":"Howard","year":"1982","journal-title":"J Exp Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1084\/jem.155.3.734","article-title":"T cell-derived B cell differentiation factor(s). Effect on the isotype switch of murine B cells","volume":"155","author":"Isakson","year":"1982","journal-title":"J Exp Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.145.11.3796","article-title":"IL-4 directs the development of Th2-like helper effectors","volume":"145","author":"Swain","year":"1990","journal-title":"J Immunol (Baltimore Md.: 1950)"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1677","article-title":"IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector T cells","volume":"9","author":"Dardalhon","year":"2008","journal-title":"Nat Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1126\/science.8266076","article-title":"Sharing of the interleukin-2 (IL-2) receptor gamma chain between receptors for IL-2 and IL-4","volume":"262","author":"Kondo","year":"1993","journal-title":"Sci (New York N.Y.)"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1126\/science.8266078","article-title":"Interleukin-2 receptor gamma chain: a functional component of the interleukin-4 receptor","volume":"262","author":"Russell","year":"1993","journal-title":"Sci (New York N.Y.)"},{"key":"B61","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.cyto.2015.05.023","article-title":"Commentary: IL-4 and IL-13 receptors and signaling","volume":"75","author":"McCormick","year":"2015","journal-title":"Cytokine"},{"key":"B62","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1073\/pnas.93.1.497","article-title":"Cloning and characterization of a binding subunit of the interleukin 13 receptor that is also a component of the interleukin 4 receptor","volume":"93","author":"Hilton","year":"1996","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00888","article-title":"Tuning the cytokine responses: an update on interleukin (IL)-4 and IL-13 receptor complexes","volume":"9","author":"Junttila","year":"2018","journal-title":"Front Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1126\/science.8085155","article-title":"An interleukin-4-induced transcription factor: IL-4 Stat","volume":"265","author":"Hou","year":"1994","journal-title":"Sci (New York N.Y.)"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(96)00835-6","article-title":"IL4 and IL13 receptors share the gamma c chain and activate STAT6, STAT3 and STAT5 proteins in normal human B cells","volume":"393","author":"Rolling","year":"1996","journal-title":"FEBS Lett"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/333571a0","article-title":"Stimulation of B-cell progenitors by cloned murine interleukin-7","volume":"333","author":"Namen","year":"1988","journal-title":"Nature"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.1.302","article-title":"Human interleukin 7: molecular cloning and growth factor activity on human and murine B-lineage cells","volume":"86","author":"Goodwin","year":"1989","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.03.021","article-title":"IL-7-induced glycerol transport and TAG synthesis promotes memory CD8+ T cell longevity","volume":"161","author":"Cui","year":"2015","journal-title":"Cell"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0479-x","article-title":"Flip the coin: IL-7 and IL-7R in health and disease","volume":"20","author":"Barata","year":"2019","journal-title":"Nat Immunol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1111\/imm.v170.4","article-title":"Interleukin-7 improves the fitness of regulatory T cells for adoptive transfer","volume":"170","author":"Cosorich","year":"2023","journal-title":"Immunology"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1126\/science.8266077","article-title":"Interleukin-2 receptor gamma chain: a functional component of the interleukin-7 receptor","volume":"262","author":"Noguchi","year":"1993","journal-title":"Sci (New York N.Y.)"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1126\/science.8128231","article-title":"Functional participation of the IL-2 receptor gamma chain in IL-7 receptor complexes","volume":"263","author":"Kondo","year":"1994","journal-title":"Sci (New York N.Y.)"},{"key":"B73","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.cyto.2007.07.183","article-title":"Interlinking interleukin-7","volume":"39","author":"Kittipatarin","year":"2007","journal-title":"Cytokine"},{"key":"B74","doi-asserted-by":"publisher","first-page":"14937","DOI":"10.1038\/ncomms14937","article-title":"Structure and antagonism of the receptor complex mediated by human TSLP in allergy and asthma","volume":"8","author":"Verstraete","year":"2017","journal-title":"Nat Commun"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1515\/bc.2010.029","article-title":"Signal transduction by the atopy-associated human thymic stromal lymphopoietin (TSLP) receptor depends on Janus kinase function","volume":"391","author":"Wohlmann","year":"2010","journal-title":"Biol Chem"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0524-9","article-title":"TSLP: from allergy to cancer","volume":"20","author":"Corren","year":"2019","journal-title":"Nat Immunol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.85.18.6934","article-title":"Functional and structural characterization of P40, a mouse glycoprotein with T-cell growth factor activity","volume":"85","author":"Uyttenhove","year":"1988","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.36.25855","article-title":"Distinct roles for STAT1, STAT3, and STAT5 in differentiation gene induction and apoptosis inhibition by interleukin-9","volume":"274","author":"Demoulin","year":"1999","journal-title":"J Biol Chem"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.15.9255","article-title":"Heteromerization of the gammac chain with the interleukin-9 receptor alpha subunit leads to STAT activation and prevention of apoptosis","volume":"273","author":"Bauer","year":"1998","journal-title":"J Biol Chem"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2004.01.006","article-title":"IL-9 increases the expression of several cytokines in activated mast cells, while the IL-9-induced IL-9 production is inhibited in mast cells of histamine-free transgenic mice","volume":"26","author":"Wiener","year":"2004","journal-title":"Cytokine"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830200632","article-title":"Mast cell growth-enhancing activity (MEA) is structurally related and functionally identical to the novel mouse T cell growth factor P40\/TCGFIII (interleukin 9)","volume":"20","author":"H\u00fcltner","year":"1990","journal-title":"Eur J Immunol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0812530106","article-title":"IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells","volume":"106","author":"Elyaman","year":"2009","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20130071","article-title":"IL-9-mediated survival of type 2 innate lymphoid cells promotes damage control in helminth-induced lung inflammation","volume":"210","author":"Turner","year":"2013","journal-title":"J Exp Med"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1126\/science.8178155","article-title":"Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor","volume":"264","author":"Grabstein","year":"1994","journal-title":"Sci (New York N.Y.)"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1994.tb06576.x","article-title":"Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15","volume":"13","author":"Giri","year":"1994","journal-title":"EMBO J"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(02)00429-6","article-title":"IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells","volume":"17","author":"Dubois","year":"2002","journal-title":"Immunity"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M011475200","article-title":"Interleukin-15 prevents mouse mast cell apoptosis through STAT6-mediated Bcl-xL expression","volume":"276","author":"Masuda","year":"2001","journal-title":"J Biol Chem"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.200360997","article-title":"Cloning of a type I cytokine receptor most related to the IL-2 receptor beta chain","volume":"97","author":"Ozaki","year":"2000","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B89","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/35040504","article-title":"Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function","volume":"408","author":"Parrish-Novak","year":"2000","journal-title":"Nature"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4049\/jimmunol.167.1.1","article-title":"Cutting edge: the common gamma-chain is an indispensable subunit of the IL-21 receptor complex","volume":"167","author":"Asao","year":"2001","journal-title":"J Immunol (Baltimore Md.: 1950)"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-054973","article-title":"The molecular basis of IL-21-mediated proliferation","volume":"109","author":"Zeng","year":"2007","journal-title":"Blood"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1511711112","article-title":"Opposing roles of STAT1 and STAT3 in IL-21 function in CD4+ T cells","volume":"112","author":"Wan","year":"2015","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1126\/science.1077002","article-title":"A critical role for IL-21 in regulating immunoglobulin production","volume":"298","author":"Ozaki","year":"2002","journal-title":"Sci (New York N.Y.)"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.1.657","article-title":"Distinct activation signals determine whether IL-21 induces B cell costimulation, growth arrest, or Bim-dependent apoptosis","volume":"173","author":"Jin","year":"2004","journal-title":"J Immunol (Baltimore Md.: 1950)"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.8.4111","article-title":"IL-21 induces the apoptosis of resting and activated primary B cells","volume":"170","author":"Mehta","year":"2003","journal-title":"J Immunol (Baltimore Md.: 1950)"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20041057","article-title":"Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function","volume":"201","author":"Zeng","year":"2005","journal-title":"J Exp Med"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003009","article-title":"Intrinsic IL-21 signaling is critical for CD8 T cell survival and memory formation in response to vaccinia viral infection","volume":"186","author":"Novy","year":"2011","journal-title":"J Immunol (Baltimore Md.: 1950)"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2008.05.009","article-title":"Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages","volume":"29","author":"Nurieva","year":"2008","journal-title":"Immunity"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1038\/nature05969","article-title":"Essential autocrine regulation by IL-21 in the generation of inflammatory T cells","volume":"448","author":"Nurieva","year":"2007","journal-title":"Nature"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-388546","article-title":"IL-21 inhibits T cell IL-2 production and impairs Treg homeostasis","volume":"119","author":"Attridge","year":"2012","journal-title":"Blood"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/S0091","article-title":"Biology of common beta receptor-signaling cytokines: IL-3, IL-5, and GM-CSF","volume":"112","author":"Martinez-Moczygemba","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.09.030","article-title":"Translating the biology of \u03b2 common receptor-engaging cytokines into clinical medicine","volume":"151","author":"Pant","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/j.1600-065X.2012.01164.x","article-title":"The GM-CSF\/IL-3\/IL-5 cytokine receptor family: from ligand recognition to initiation of signaling","volume":"250","author":"Broughton","year":"2012","journal-title":"Immunol Rev"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2015.02.005","article-title":"The \u03b2c receptor family - Structural insights and their functional implications","volume":"74","author":"Broughton","year":"2015","journal-title":"Cytokine"},{"key":"B105","doi-asserted-by":"publisher","first-page":"101510","DOI":"10.1016\/j.smim.2021.101510","article-title":"IL-3 in the development and function of basophils","volume":"54","author":"Varricchi","year":"2021","journal-title":"Semin Immunol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1159\/000070921","article-title":"Molecular mechanisms of dendritic cell sublineage development from human hematopoietic progenitor\/stem cells","volume":"131","author":"Strobl","year":"2003","journal-title":"Int Arch Allergy Immunol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.12.6199","article-title":"A novel role for IL-3: human monocytes cultured in the presence of IL-3 and IL-4 differentiate into dendritic cells that produce less IL-12 and shift Th cell responses toward a Th2 cytokine pattern","volume":"168","author":"Ebner","year":"2002","journal-title":"J Immunol (Baltimore Md.: 1950)"},{"key":"B108","article-title":"IL-5 enhances the in vitro adhesion of human eosinophils, but not neutrophils, in a leucocyte integrin (CD11\/18)-dependent manner","volume":"71","author":"Walsh","year":"1990","journal-title":"Immunology"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.2183\/pjab.87.463","article-title":"Interleukin-5 and IL-5 receptor in health and diseases","volume":"87","author":"Takatsu","year":"2011","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2003.108","article-title":"2. Cytokines and chemokines","volume":"111","author":"Borish","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20021843","article-title":"Enforced granulocyte\/macrophage colony-stimulating factor signals do not support lymphopoiesis, but instruct lymphoid to myelomonocytic lineage conversion","volume":"197","author":"Iwasaki-Arai","year":"2003","journal-title":"J Exp Med"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1007\/s004030100225","article-title":"GM-CSF downmodulates c-kit, Fc(epsilon)RI(alpha) and GM-CSF receptor expression as well as histamine and tryptase levels in cultured human mast cells","volume":"293","author":"Welker","year":"2001","journal-title":"Arch Dermatol Res"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.03.027","article-title":"Pleiotropy and specificity: insights from the interleukin 6 family of cytokines","volume":"50","author":"Murakami","year":"2019","journal-title":"Immunity"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1042\/bj20030407","article-title":"Principles of interleukin (IL)-6-type cytokine signalling and its regulation","volume":"374","author":"Heinrich","year":"2003","journal-title":"Biochem J"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1038\/nsmb941","article-title":"Signaling conformations of the tall cytokine receptor gp130 when in complex with IL-6 and IL-6 receptor","volume":"12","author":"Skiniotis","year":"2005","journal-title":"Nat Struct Mol Biol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190347","article-title":"Historical overview of the interleukin-6 family cytokine","volume":"217","author":"Kang","year":"2020","journal-title":"J Exp Med"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2008.08.003","article-title":"Structures and biological functions of IL-31 and IL-31 receptors","volume":"19","author":"Zhang","year":"2008","journal-title":"Cytokine Growth factor Rev"},{"key":"B118","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1126\/science.8272872","article-title":"Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130","volume":"263","author":"L\u00fctticken","year":"1994","journal-title":"Sci (New York N.Y.)"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1126\/science.8272873","article-title":"Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components","volume":"263","author":"Stahl","year":"1994","journal-title":"Sci (New York N.Y.)"},{"key":"B120","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1042\/bj3340297","article-title":"Interleukin-6-type cytokine signalling through the gp130\/Jak\/STAT pathway","volume":"334","author":"Heinrich","year":"1998","journal-title":"Biochem J"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.25.14847","article-title":"Separate signaling mechanisms are involved in the control of STAT protein activation and gene regulation via the interleukin 6 response element by the box 3 motif of gp130","volume":"270","author":"Lai","year":"1995","journal-title":"J Biol Chem"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.04.014","article-title":"Asymmetric action of STAT transcription factors drives transcriptional outputs and cytokine specificity","volume":"42","author":"Hirahara","year":"2015","journal-title":"Immunity"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.153.1.128","article-title":"Expression cloning of a human IL-12 receptor component. A new member of the cytokine receptor superfamily with strong homology to gp130","volume":"153","author":"Chua","year":"1994","journal-title":"J Immunol (Baltimore Md.: 1950)"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1084\/jem.170.3.827","article-title":"Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes","volume":"170","author":"Kobayashi","year":"1989","journal-title":"J Exp Med"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.24.14002","article-title":"A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits","volume":"93","author":"Presky","year":"1996","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1038\/382171a0","article-title":"Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells","volume":"382","author":"Thierfelder","year":"1996","journal-title":"Nature"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1126\/science.8097338","article-title":"Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages","volume":"260","author":"Hsieh","year":"1993","journal-title":"Sci (New York N.Y.)"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1038\/nri1001","article-title":"Interleukin-12 and the regulation of innate resistance and adaptive immunity","volume":"3","author":"Trinchieri","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)00070-4","article-title":"Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12","volume":"13","author":"Oppmann","year":"2000","journal-title":"Immunity"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.432153","article-title":"Identification of canonical tyrosine-dependent and non-canonical tyrosine-independent STAT3 activation sites in the intracellular domain of the interleukin 23 receptor","volume":"288","author":"Floss","year":"2013","journal-title":"J Biol Chem"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.11.5699","article-title":"A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R","volume":"168","author":"Parham","year":"2002","journal-title":"J Immunol (Baltimore Md.: 1950)"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M207577200","article-title":"Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17","volume":"278","author":"Aggarwal","year":"2003","journal-title":"J Biol Chem"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2422","article-title":"Interferons at age 50: past, current and future impact on biomedicine","volume":"6","author":"Borden","year":"2007","journal-title":"Nat Rev Drug Discovery"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1126\/science.8197455","article-title":"Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins","volume":"264","author":"Darnell","year":"1994","journal-title":"Sci (New York N.Y.)"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1038\/nri3806","article-title":"Regulation of antiviral T cell responses by type I interferons","volume":"15","author":"Crouse","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1126\/science.1235214","article-title":"Persistent LCMV infection is controlled by blockade of type I interferon signaling","volume":"340","author":"Teijaro","year":"2013","journal-title":"Sci (New York N.Y.)"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(01)00126-1","article-title":"Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo","volume":"14","author":"Le Bon","year":"2001","journal-title":"Immunity"},{"key":"B138","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1084\/jem.187.1.79","article-title":"Impairment of T and B cell development by treatment with a type I interferon","volume":"187","author":"Lin","year":"1998","journal-title":"J Exp Med"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aah6817","article-title":"Interferon-driven deletion of antiviral B cells at the onset of chronic infection","volume":"1","author":"Fallet","year":"2016","journal-title":"Sci Immunol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2006.08.014","article-title":"Complex modulation of cell type-specific signaling in response to type I interferons","volume":"25","author":"van-Boxel-Dezaire","year":"2006","journal-title":"Immunity"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1038\/nri1604","article-title":"Mechanisms of type-I- and type-II-interferon-mediated signalling","volume":"5","author":"Platanias","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1034\/j.1398-9995.1999.00099.x","article-title":"Biologic functions of the IFN-gamma receptors","volume":"54","author":"Tau","year":"1999","journal-title":"Allergy"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-018-0029-z","article-title":"IFN\u03b3: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy","volume":"18","author":"Ivashkiv","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.03.025","article-title":"Shared and distinct functions of type I and type III interferons","volume":"50","author":"Lazear","year":"2019","journal-title":"Immunity"},{"key":"B145","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/ni875","article-title":"IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex","volume":"4","author":"Kotenko","year":"2003","journal-title":"Nat Immunol"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1038\/emboj.2013.232","article-title":"Interferon lambda 4 signals via the IFN\u03bb receptor to regulate antiviral activity against HCV and coronaviruses","volume":"32","author":"Hamming","year":"2013","journal-title":"EMBO J"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1038\/ni873","article-title":"IL-28, IL-29 and their class II cytokine receptor IL-28R","volume":"4","author":"Sheppard","year":"2003","journal-title":"Nat Immunol"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3212","article-title":"Guarding the frontiers: the biology of type III interferons","volume":"16","author":"Wack","year":"2015","journal-title":"Nat Immunol"},{"key":"B149","doi-asserted-by":"publisher","first-page":"101303","DOI":"10.1016\/j.smim.2019.101303","article-title":"Type III IFNs: Beyond antiviral protection","volume":"43","author":"Kotenko","year":"2019","journal-title":"Semin Immunol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20140995","article-title":"IFN-\u03bb resolves inflammation via suppression of neutrophil infiltration and IL-1\u03b2 production","volume":"212","author":"Blazek","year":"2015","journal-title":"J Exp Med"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1002\/emmm.201100142","article-title":"IL-28A (IFN-\u03bb2) modulates lung DC function to promote Th1 immune skewing and suppress allergic airway disease","volume":"3","author":"Koltsida","year":"2011","journal-title":"EMBO Mol Med"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2010.11.001","article-title":"IL-10 family of cytokines","volume":"21","author":"Sabat","year":"2010","journal-title":"Cytokine Growth factor Rev"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.23.11267","article-title":"A receptor for interleukin 10 is related to interferon receptors","volume":"90","author":"Ho","year":"1993","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/16.19.5894","article-title":"Identification and functional characterization of a second chain of the interleukin-10 receptor complex","volume":"16","author":"Kotenko","year":"1997","journal-title":"EMBO J"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.155.3.1079","article-title":"IL-10 induces the tyrosine phosphorylation of tyk2 and Jak1 and the differential assembly of STAT1 alpha and STAT3 complexes in human T cells and monocytes","volume":"155","author":"Finbloom","year":"1995","journal-title":"J Immunol (Baltimore Md.: 1950)"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-031210-101312","article-title":"Regulation and functions of the IL-10 family of cytokines in inflammation and disease","volume":"29","author":"Ouyang","year":"2011","journal-title":"Annu Rev Immunol"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.03.020","article-title":"IL-10 family cytokines IL-10 and IL-22: from basic science to clinical translation","volume":"50","author":"Ouyang","year":"2019","journal-title":"Immunity"},{"key":"B158","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1146\/annurev.immunol.19.1.683","article-title":"Interleukin-10 and the interleukin-10 receptor","volume":"19","author":"Moore","year":"2001","journal-title":"Annu Rev Immunol"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1038\/nri3766","article-title":"The IL-20 subfamily of cytokines\u2013from host defence to tissue homeostasis","volume":"14","author":"Rutz","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.22.012703.104622","article-title":"Interleukin-10 and related cytokines and receptors","volume":"22","author":"Pestka","year":"2004","journal-title":"Annu Rev Immunol"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.4.2229","article-title":"The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis","volume":"178","author":"Sa","year":"2007","journal-title":"J Immunol (Baltimore Md.: 1950)"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.11.6712","article-title":"IL-19 induced Th2 cytokines and was up-regulated in asthma patients","volume":"173","author":"Liao","year":"2004","journal-title":"J Immunol (Baltimore Md.: 1950)"},{"key":"B163","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40591-016-0046-x","article-title":"Interleukin 20 regulates dendritic cell migration and expression of co-stimulatory molecules","volume":"4","author":"Bech","year":"2016","journal-title":"Mol Cell Ther"},{"key":"B164","doi-asserted-by":"publisher","first-page":"5820","DOI":"10.1038\/s41467-022-33331-8","article-title":"Interleukin-22 regulates neutrophil recruitment in ulcerative colitis and is associated with resistance to ustekinumab therapy","volume":"13","author":"Pavlidis","year":"2022","journal-title":"Nat Commun"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.12.6041","article-title":"The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24","volume":"168","author":"Caudell","year":"2002","journal-title":"J Immunol (Baltimore Md.: 1950)"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-220251","article-title":"Interleukin-24 inhibits the plasma cell differentiation program in human germinal center B cells","volume":"115","author":"Maarof","year":"2010","journal-title":"Blood"},{"key":"B167","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cytogfr.2019.01.001","article-title":"Emerging role of immune cell network in autoimmune skin disorders: An update on pemphigus, vitiligo and psoriasis","volume":"45","author":"Das","year":"2019","journal-title":"Cytokine Growth Factor Rev"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-103019-085803","article-title":"In vivo CD4+ T cell differentiation and function: revisiting the th1\/th2 paradigm","volume":"38","author":"Ruterbusch","year":"2020","journal-title":"Annu Rev Immunol"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.1.635","article-title":"Dichotomy of autoreactive Th1 and Th2 cell responses to desmoglein 3 in patients with pemphigus vulgaris (PV) and healthy carriers of PV-associated HLA class II alleles","volume":"170","author":"Veldman","year":"2003","journal-title":"J Immunol (Baltimore Md.: 1950)"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.11.5239","article-title":"Correlation of peptide specificity and IgG subclass with pathogenic and nonpathogenic autoantibodies in pemphigus vulgaris: a model for autoimmunity","volume":"92","author":"Bhol","year":"1995","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.2.1526","article-title":"Novel system evaluating in vivo pathogenicity of desmoglein 3-reactive T cell clones using murine pemphigus vulgaris","volume":"181","author":"Takahashi","year":"2008","journal-title":"J Immunol (Baltimore Md.: 1950)"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.25.11935","article-title":"Structural basis for major histocompatibility complex (MHC)-linked susceptibility to autoimmunity: charged residues of a single MHC binding pocket confer selective presentation of self-peptides in pemphigus vulgaris","volume":"92","author":"Wucherpfennig","year":"1995","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2005.01836.x","article-title":"Direct characterization of human T cells in pemphigus vulgaris reveals elevated autoantigen-specific Th2 activity in association with active disease","volume":"30","author":"Rizzo","year":"2005","journal-title":"Clin Exp Dermatol"},{"key":"B174","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1080\/08820130902943097","article-title":"Involvement of T(H)1\/T(H)2 cytokines in the pathogenesis of autoimmune skin disease-Pemphigus vulgaris","volume":"38","author":"Satyam","year":"2009","journal-title":"Immunol investigations"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2007.12.007","article-title":"Cytokine profiles in pemphigus vulgaris patients treated with intravenous immunoglobulins as compared to conventional immunosuppressive therapy","volume":"41","author":"Keskin","year":"2008","journal-title":"Cytokine"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2015.09.017","article-title":"Interleukin 4 inhibition as a potential therapeutic in pemphigus","volume":"77","author":"Tavakolpour","year":"2016","journal-title":"Cytokine"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2022.10.035","article-title":"Dupilumab monotherapy suppresses recalcitrant pemphigus vulgaris","volume":"31","author":"Moore","year":"2023","journal-title":"JAAD Case Rep"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2023.09.018","article-title":"Novel use of dupilumab in pemphigus vulgaris and pemphigus foliaceus","volume":"42","author":"Jiang","year":"2023","journal-title":"JAAD Case Rep"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.825796","article-title":"A novel combined use of dupilumab for treatment of aggressive refractory pemphigus vulgaris complicated with pulmonary tuberculosis: A case report and the RNA-seq analysis","volume":"13","author":"Chen","year":"2022","journal-title":"Front Immunol"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1016\/0952-7915(95)80050-6","article-title":"The Th1\/Th2 balance in autoimmunity","volume":"7","author":"Charlton","year":"1995","journal-title":"Curr Opin Immunol"},{"key":"B181","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1172\/JCI119130","article-title":"Development and characterization of desmoglein-3 specific T cells from patients with pemphigus vulgaris","volume":"99","author":"Lin","year":"1997","journal-title":"J Clin Invest"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2017.29.4.438","article-title":"Analysis of serum cytokine profile in pemphigus","volume":"29","author":"Lee","year":"2017","journal-title":"Ann Dermatol"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700527","article-title":"T helper type 2-biased natural killer cell phenotype in patients with pemphigus vulgaris","volume":"127","author":"Takahashi","year":"2007","journal-title":"J Invest Dermatol"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2008.09.008","article-title":"Lesional Th17 cells in pemphigus vulgaris and pemphigus foliaceus","volume":"53","author":"Arakawa","year":"2009","journal-title":"J Dermatol Sci"},{"key":"B185","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1684\/ejd.2013.2177","article-title":"The imbalance of Th17 and regulatory T cells in pemphigus patients","volume":"23","author":"Xu","year":"2013","journal-title":"Eur J dermatology: EJD"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.11.008","article-title":"Immunophenotyping in pemphigus reveals a TH17\/TFH17 cell-dominated immune response promoting desmoglein1\/3-specific autoantibody production","volume":"147","author":"Holstein","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.05.032","article-title":"Pivotal role of lesional and perilesional T\/B lymphocytes in pemphigus pathogenesis","volume":"137","author":"Yuan","year":"2017","journal-title":"J Invest Dermatol"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.979277","article-title":"Detection of rare autoreactive T cell subsets in patients with pemphigus vulgaris","volume":"13","author":"Polakova","year":"2022","journal-title":"Front In Immunol"},{"key":"B189","article-title":"The effect of conventional immunosuppressive therapy on cytokine serum levels in pemphigus vulgaris patients","volume":"13","author":"Mortazavi","year":"2014","journal-title":"Iran J Allergy Asthma Immunol"},{"key":"B190","doi-asserted-by":"publisher","first-page":"7151285","DOI":"10.1155\/2017\/7151285","article-title":"Th1\/th17-related cytokines and chemokines and their implications in the pathogenesis of pemphigus vulgaris","volume":"2017","author":"Timoteo","year":"2017","journal-title":"Mediators Inflamm"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2015.06.008","article-title":"Distinctive Treg associated CCR4-CCL22 expression profile with altered frequency of Th17\/Treg cell in the immunopathogenesis of Pemphigus Vulgaris","volume":"220","author":"Asothai","year":"2015","journal-title":"Immunobiology"},{"key":"B192","doi-asserted-by":"publisher","first-page":"463928","DOI":"10.1155\/2014\/463928","article-title":"Overexpression of interleukin-23 and interleukin-17 in the lesion of pemphigus vulgaris: a preliminary study","volume":"2014","author":"Xue","year":"2014","journal-title":"Mediators Inflammation"},{"key":"B193","doi-asserted-by":"publisher","first-page":"15","DOI":"10.5070\/D39hw6p904","article-title":"Th-17 and the lack of efficacy of ustekinumab in pemphigus vulgaris","volume":"19","author":"Tirado-S\u00e1nchez","year":"2013","journal-title":"Dermatol Online J"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2012.58","article-title":"Follicular helper T cells in immunity and systemic autoimmunity","volume":"8","author":"Craft","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0148919","article-title":"Increased frequency of T follicular helper cells and elevated interleukin-27 plasma levels in patients with pemphigus","volume":"11","author":"Hennerici","year":"2016","journal-title":"PloS One"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.03.036","article-title":"Targeting inducible costimulator expressed on CXCR5+PD-1+ TH cells suppresses the progression of pemphigus vulgaris","volume":"146","author":"Kim","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.v37.12","article-title":"Circulating Tfr\/Tfh cell imbalance may contribute to the immunopathogenesis of pemphigus","volume":"37","author":"Wang","year":"2023","journal-title":"J Eur Acad Dermatol Venereology: JEADV"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.1998.00156.x","article-title":"Heterogeneous MHC II restriction pattern of autoreactive desmoglein 3 specific T cell responses in pemphigus vulgaris patients and normals","volume":"110","author":"Hertl","year":"1998","journal-title":"J Invest Dermatol"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.6.3883","article-title":"T cell recognition of desmoglein 3 peptides in patients with pemphigus vulgaris and healthy individuals","volume":"172","author":"Veldman","year":"2004","journal-title":"J Immunol (Baltimore Md.: 1950)"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.10.6468","article-title":"Type I regulatory T cells specific for desmoglein 3 are more frequently detected in healthy individuals than in patients with pemphigus vulgaris","volume":"172","author":"Veldman","year":"2004","journal-title":"J Immunol (Baltimore Md.: 1950)"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2023.01.004","article-title":"Principles of regulatory T cell function","volume":"56","author":"Dikiy","year":"2023","journal-title":"Immunity"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1159\/000099585","article-title":"CD4+CD25high regulatory T cells are markedly decreased in blood of patients with pemphigus vulgaris","volume":"214","author":"Sugiyama","year":"2007","journal-title":"Dermatol (Basel Switzerland)"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2008.03035.x","article-title":"CD28 T-cell costimulatory molecule expression in pemphigus vulgaris","volume":"23","author":"Alecu","year":"2009","journal-title":"J Eur Acad Dermatol Venereology: JEADV"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxr020","article-title":"Antigen-independent development of Foxp3+ regulatory T cells suppressing autoantibody production in experimental pemphigus vulgaris","volume":"23","author":"Yokoyama","year":"2011","journal-title":"Int Immunol"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2026763118","article-title":"Peripheral tolerance by Treg via constraining OX40 signal in autoreactive T cells against desmoglein 3, a target antigen in pemphigus","volume":"118","author":"Iriki","year":"2021","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.5005\/jp-journals-10024-1610","article-title":"Evaluation of interleukin-1\u03b1, interleukin-10, tumor necrosis factor-\u03b1 and transforming growth factor-\u03b2 in the serum of patients with pemphigus vulgaris","volume":"15","author":"Khozeimeh","year":"2014","journal-title":"J Contemp Dent Pract"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.03.009","article-title":"Serum and blister fluid levels of cytokines and chemokines in pemphigus and bullous pemphigoid","volume":"18","author":"Kowalski","year":"2019","journal-title":"Autoimmun Rev"},{"key":"B208","article-title":"Cytokines in the sera of patients with pemphigus vulgaris: interleukin-6 and tumour necrosis factor-alpha levels are significantly increased as compared to healthy subjects and correlate with disease activity","volume":"8","author":"D\u2019Auria","year":"1997","journal-title":"Eur Cytokine Netw"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1006\/clim.2001.5061","article-title":"Pemphigus vulgaris: the role of IL-1 and IL-1 receptor antagonist in pathogenesis and effects of intravenous immunoglobulin on their production","volume":"100","author":"Bhol","year":"2001","journal-title":"Clin Immunol (Orlando Fla.)"},{"key":"B210","article-title":"Anti-intercellular substance antibody log titres are correlated with serum concentrations of interleukin-6, interleukin-15 and tumor necrosis factor-alpha in patients with Pemphigus vulgaris relationships with peripheral blood neutrophil counts, disease severity and duration and patients\u2019 age","volume":"13","author":"Ameglio","year":"1999","journal-title":"J Biol Regul Homeost Agents"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2000.00835.x","article-title":"In vitro and in vivo expression of interleukin-1alpha and tumor necrosis factor-alpha mRNA in pemphigus vulgaris: interleukin-1alpha and tumor necrosis factor-alpha are involved in acantholysis","volume":"114","author":"Feliciani","year":"2000","journal-title":"J Invest Dermatol"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.2001.01083.x","article-title":"TNFalpha and IL-6 are mediators in the blistering process of pemphigus","volume":"40","author":"L\u00f3pez-Robles","year":"2001","journal-title":"Int J Dermatol"},{"key":"B213","article-title":"ICAM-1, ELAM-1, TNF-alpha and IL-6 in serum and blister liquid of pemphigus vulgaris patients","volume":"58","author":"Alecu","year":"1999","journal-title":"Roum Arch Microbiol Immunol"},{"key":"B214","doi-asserted-by":"publisher","first-page":"875394","DOI":"10.1155\/2008\/875394","article-title":"Serum concentration of interleukin-6 is increased both in active and remission stages of pemphigus vulgaris","author":"Narbutt","year":"2008","journal-title":"Mediators Inflamm 2008"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.04319.x","article-title":"The influence of systemic therapy on the serum levels of IL-6 and IL-8 in pemphigus vulgaris","volume":"27","author":"Mortazavi","year":"2013","journal-title":"J Eur Acad Dermatol Venereology: JEADV"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0625.2002.120415.x","article-title":"Urokinase plasminogen activator mRNA is induced by IL-1alpha and TNF-alpha in in vitro acantholysis","volume":"12","author":"Feliciani","year":"2003","journal-title":"Exp Dermatol"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.v184.6","article-title":"ST18 affects cell-cell adhesion in pemphigus vulgaris in a tumour necrosis factor-\u03b1-dependent fashion","volume":"184","author":"Assaf","year":"2021","journal-title":"Br J Dermatol"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2010.409","article-title":"A pilot study of etanercept treatment for pemphigus vulgaris","volume":"147","author":"Fiorentino","year":"2011","journal-title":"Arch Dermatol"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06672.x","article-title":"Infliximab in the management of severe pemphigus vulgaris","volume":"153","author":"Pardo","year":"2005","journal-title":"Br J Dermatol"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06744.x","article-title":"Rapid control of therapy-refractory pemphigus vulgaris by treatment with the tumour necrosis factor-alpha inhibitor infliximab","volume":"153","author":"Jacobi","year":"2005","journal-title":"Br J Dermatol"},{"key":"B221","article-title":"Successful treatment of pemphigus vulgaris with etanercept in four patients","volume":"8","author":"Shetty","year":"2009","journal-title":"J Drugs Dermatol"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llad173","article-title":"Sarilumab (interleukin-6 receptor monoclonal antibody) for the treatment of pemphigus vulgaris","volume":"48","author":"Andrew","year":"2023","journal-title":"Clin Exp Dermatol"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis","volume":"397","author":"Ghoreschi","year":"2021","journal-title":"Lancet (London England)"},{"key":"B224","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/all.13954","article-title":"Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis","volume":"75","author":"Bieber","year":"2020","journal-title":"Allergy"},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017.22","article-title":"Beyond TNF: TNF superfamily cytokines as targets for the treatment of Rheumatic diseases","volume":"13","author":"Croft","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-020-09122-y","article-title":"Expression of JAK3, STAT2, STAT4, and STAT6 in pemphigus vulgaris","volume":"68","author":"Juczynska","year":"2020","journal-title":"Immunol Res"},{"key":"B227","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3390\/ijms24010323","article-title":"Expression of the selected proteins of JAK\/STAT signaling pathway in diseases with oral mucosa involvement","volume":"24","author":"Ociepa","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B228","doi-asserted-by":"publisher","first-page":"e12696","DOI":"10.1111\/dth.12696","article-title":"Tofacitinib as the potent treatment for refractory pemphigus: A possible alternative treatment for pemphigus","volume":"31","author":"Tavakolpour","year":"2018","journal-title":"Dermatol Ther"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-207201","article-title":"Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors","volume":"75","author":"Gao","year":"2016","journal-title":"Ann Rheumatic Dis"},{"key":"B230","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203756","article-title":"The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells","volume":"73","author":"Kubo","year":"2014","journal-title":"Ann Rheumatic Dis"},{"key":"B231","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.12.1318","article-title":"Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study","volume":"137","author":"Krueger","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.030423","article-title":"Inhibition of JAK-STAT signaling suppresses pathogenic immune responses in medium and large vessel vasculitis","volume":"137","author":"Zhang","year":"2018","journal-title":"Circulation"},{"key":"B233","doi-asserted-by":"publisher","DOI":"10.1159\/000525462","article-title":"Nail loss in mild to moderate pemphigus vulgaris","volume":"8","author":"Vander Does","year":"2022","journal-title":"Skin Appendage Disord"},{"key":"B234","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.17464","article-title":"Upadacitinib leading to resolution of refractory mucosal erosions in a case of pemphigus vulgaris","volume":"64","author":"Hren","year":"2025","journal-title":"Int J Dermatol"},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16654","article-title":"What\u2019s new in the pathogeneses and triggering factors of bullous pemphigoid","volume":"50","author":"Ujiie","year":"2023","journal-title":"J Dermatol"},{"key":"B236","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1161927","article-title":"Understanding CD4+ T cells in autoimmune bullous diseases","volume":"14","author":"Lee","year":"2023","journal-title":"Front Immunol"},{"key":"B237","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2017.07.012","article-title":"IgG4, complement, and the mechanisms of blister formation in pemphigus and bullous pemphigoid","volume":"88","author":"Dainichi","year":"2017","journal-title":"J Dermatol Sci"},{"key":"B238","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.912876","article-title":"Insights into the pathogenesis of bullous pemphigoid: the role of complement-independent mechanisms","volume":"13","author":"Cole","year":"2022","journal-title":"Front Immunol"},{"key":"B239","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1998.02169.x","article-title":"Cytokine pattern in blister fluid and serum of patients with bullous pemphigoid: relationships with disease intensity","volume":"138","author":"Ameglio","year":"1998","journal-title":"Br J Dermatol"},{"key":"B240","doi-asserted-by":"publisher","DOI":"10.1007\/BF02507102","article-title":"Detection of elevated levels of IL-4, IL-6, and IL-10 in blister fluid of bullous pemphigoid","volume":"288","author":"Schmidt","year":"1996","journal-title":"Arch Dermatol Res"},{"key":"B241","doi-asserted-by":"publisher","DOI":"10.1046\/j.0022-202x.2001.01505.x","article-title":"Skin-homing interleukin-4 and -13-producing cells contribute to bullous pemphigoid: remission of disease is associated with increased frequency of interleukin-10-producing cells","volume":"117","author":"Teraki","year":"2001","journal-title":"J Invest Dermatol"},{"key":"B242","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1177\/205873929901200202","article-title":"A Th2-like cytokine response is involved in bullous pemphigoid. the role of IL-4 and IL-5 in the pathogenesis of the disease","volume":"12","author":"Feliciani","year":"1999","journal-title":"Int J Immunopathol Pharmacol"},{"key":"B243","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/cei.12566","article-title":"T cell participation in autoreactivity to NC16a epitopes in bullous pemphigoid","volume":"180","author":"Pickford","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"B244","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.03.1515","article-title":"Identification of immunodominant th2-cell epitopes in chinese patients with bullous pemphigoid","volume":"138","author":"Zhang","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B245","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.824110","article-title":"IL-13 genetic susceptibility to bullous pemphigoid: A potential target for treatment and a prognostic marker","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"B246","doi-asserted-by":"publisher","DOI":"10.1080\/08820139.2020.1832113","article-title":"Association between TH2 cytokine gene polymorphisms and risk of bullous pemphigoid","volume":"51","author":"Tabatabaei-Panah","year":"2022","journal-title":"Immunol investigations"},{"key":"B247","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jaad.2019.07.060","article-title":"Pathophysiologic mechanisms of itch in bullous pemphigoid","volume":"83","author":"Hashimoto","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B248","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.2526","article-title":"Dupilumab for the treatment of recalcitrant bullous pemphigoid","volume":"154","author":"Kaye","year":"2018","journal-title":"JAMA Dermatol"},{"key":"B249","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.2428","article-title":"Evaluation of dupilumab in patients with bullous pemphigoid","volume":"159","author":"Zhao","year":"2023","journal-title":"JAMA Dermatol"},{"key":"B250","doi-asserted-by":"publisher","first-page":"111157","DOI":"10.1016\/j.intimp.2023.111157","article-title":"Long-term efficacy and safety of dupilumab for severe bullous pemphigoid: A prospective cohort study","volume":"125","author":"Huang","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B251","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.928621","article-title":"Rituximab, omalizumab, and dupilumab treatment outcomes in bullous pemphigoid: A systematic review","volume":"13","author":"Cao","year":"2022","journal-title":"Front In Immunol"},{"key":"B252","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaad.2020.01.089","article-title":"Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series","volume":"83","author":"Abdat","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B253","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.v36.10","article-title":"Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)","volume":"36","author":"Borradori","year":"2022","journal-title":"J Eur Acad Dermatol Venereology: JEADV"},{"key":"B254","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-02886-x","article-title":"Study design of a phase 2\/3 randomized controlled trial of dupilumab in adults with bullous pemphigoid: LIBERTY-BP ADEPT","volume":"41","author":"Murrell","year":"2024","journal-title":"Adv Ther"},{"key":"B255","unstructured":"Press Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study"},{"key":"B256","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llad331","article-title":"Rapid and sustained response to tralokinumab in a patient with severe bullous pemphigoid and end-stage kidney disease","volume":"49","author":"Maglie","year":"2024","journal-title":"Clin Exp Dermatol"},{"key":"B257","doi-asserted-by":"publisher","DOI":"10.1007\/s004030050272","article-title":"IL-5 levels in the serum and blister fluid of patients with bullous pemphigoid: correlations with eosinophil cationic protein, RANTES, IgE and disease severity","volume":"290","author":"D\u2019Auria","year":"1998","journal-title":"Arch Dermatol Res"},{"key":"B258","doi-asserted-by":"publisher","DOI":"10.1111\/all.2017.72.issue-7","article-title":"Evidence for a role of eosinophils in blister formation in bullous pemphigoid","volume":"72","author":"de Graauw","year":"2017","journal-title":"Allergy"},{"key":"B259","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2000.03599.x","article-title":"Elevated levels of eotaxin and interleukin-5 in blister fluid of bullous pemphigoid: correlation with tissue eosinophilia","volume":"143","author":"Wakugawa","year":"2000","journal-title":"Br J Dermatol"},{"key":"B260","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00049","article-title":"Targeting the interleukin-5 pathway for treatment of eosinophilic conditions other than asthma","volume":"5","author":"Roufosse","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"B261","doi-asserted-by":"publisher","DOI":"10.1111\/all.13950","article-title":"Mepolizumab failed to affect bullous pemphigoid: A randomized, placebo-controlled, double-blind phase 2 pilot study","volume":"75","author":"Simon","year":"2020","journal-title":"Allergy"},{"key":"B262","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13223-021-00619-1","article-title":"Successful induction treatment of bullous pemphigoid using reslizumab: a case report","volume":"17","author":"Rhyou","year":"2021","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B263","doi-asserted-by":"publisher","DOI":"10.5021\/ad.21.177","article-title":"Refractory bullous pemphigoid successfully treated with reslizumab: A possible novel therapeutic modality","volume":"35","author":"Kwon","year":"2023","journal-title":"Ann Dermatol"},{"key":"B264","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16811","article-title":"A case of bullous pemphigoid developing under treatment with benralizumab for bronchial asthma","volume":"50","author":"Tanaka","year":"2023","journal-title":"J Dermatol"},{"key":"B265","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01383","article-title":"Role of the pruritic cytokine IL-31 in autoimmune skin diseases","volume":"10","author":"Gibbs","year":"2019","journal-title":"Front In Immunol"},{"key":"B266","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2951","article-title":"Eosinophils are a major source of interleukin-31 in bullous pemphigoid","volume":"98","author":"R\u00fcdrich","year":"2018","journal-title":"Acta dermato-venereologica"},{"key":"B267","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2017.07.019","article-title":"Elevated IL-31 serum levels in bullous pemphigoid patients correlate with eosinophil numbers and are associated with BP180-IgE","volume":"87","author":"Salz","year":"2017","journal-title":"J Dermatol Sci"},{"key":"B268","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2015.106","article-title":"IL-31 induces chemotaxis, calcium mobilization, release of reactive oxygen species, and CCL26 in eosinophils, which are capable to release IL-31","volume":"135","author":"Kunsleben","year":"2015","journal-title":"J Invest Dermatol"},{"key":"B269","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01741-z","article-title":"Nemolizumab: first approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"key":"B270","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.alit.2020.01.001","article-title":"Anti-TSLP antibodies: Targeting a master regulator of type 2 immune responses","volume":"69","author":"Nakajima","year":"2020","journal-title":"Allergol Int"},{"key":"B271","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1721805115","article-title":"BP180 dysfunction triggers spontaneous skin inflammation in mice","volume":"115","author":"Zhang","year":"2018","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B272","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-019-01954-5","article-title":"Epidermal expression of eotaxins and thymic stromal lymphopoietin in eosinophil rich dermatoses","volume":"311","author":"Valdebran","year":"2019","journal-title":"Arch Dermatol Res"},{"key":"B273","doi-asserted-by":"publisher","first-page":"4594630","DOI":"10.1155\/2020\/4594630","article-title":"Thymic stromal lymphopoietin is implicated in the pathogenesis of bullous pemphigoid by dendritic cells","volume":"2020","author":"Li","year":"2020","journal-title":"J Immunol Res"},{"key":"B274","doi-asserted-by":"publisher","first-page":"9242383","DOI":"10.1155\/2022\/9242383","article-title":"Expression of thymic stromal lymphopoietin in immune-related dermatoses","volume":"2022","author":"Li","year":"2022","journal-title":"Mediators Inflammation"},{"key":"B275","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01679-2","article-title":"Tezepelumab: first approval","volume":"82","author":"Hoy","year":"2022","journal-title":"Drugs"},{"key":"B276","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2011.01378.x","article-title":"Lesional Th17 cells and regulatory T cells in bullous pemphigoid","volume":"20","author":"Arakawa","year":"2011","journal-title":"Exp Dermatol"},{"key":"B277","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.263","article-title":"Innate immune cell-produced IL-17 sustains inflammation in bullous pemphigoid","volume":"134","author":"Le Jan","year":"2014","journal-title":"J Invest Dermatol"},{"key":"B278","doi-asserted-by":"publisher","first-page":"967987","DOI":"10.1155\/2013\/967987","article-title":"IL-17 expression in dermatitis herpetiformis and bullous pemphigoid","volume":"2013","author":"Zebrowska","year":"2013","journal-title":"Mediators Inflammation"},{"key":"B279","doi-asserted-by":"publisher","first-page":"8980534","DOI":"10.1155\/2017\/8980534","article-title":"Correlation between IL36\u03b1 and IL17 and activity of the disease in selected autoimmune blistering diseases","volume":"2017","author":"\u017bebrowska","year":"2017","journal-title":"Mediators Inflammation"},{"key":"B280","doi-asserted-by":"publisher","first-page":"18001","DOI":"10.1038\/srep18001","article-title":"Integrating longitudinal serum IL-17 and IL-23 follow-up, along with autoantibodies variation, contributes to predict bullous pemphigoid outcome","volume":"5","author":"Pl\u00e9e","year":"2015","journal-title":"Sci Rep"},{"key":"B281","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.v8.12","article-title":"TH17\/IL23 cytokine gene polymorphisms in bullous pemphigoid","volume":"8","author":"Tabatabaei-Panah","year":"2020","journal-title":"Mol Genet Genomic Med"},{"key":"B282","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2022.07.019","article-title":"Absence of NC14A domain of COLXVII\/BP180 in mice results in IL-17\u2013Associated skin inflammation","volume":"143","author":"Lindgren","year":"2023","journal-title":"J Invest Dermatol"},{"key":"B283","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2018.09.003","article-title":"IL-17A is functionally relevant and a potential therapeutic target in bullous pemphigoid","volume":"96","author":"Chakievska","year":"2019","journal-title":"J Autoimmun"},{"key":"B284","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.08.012","article-title":"Bullous pemphigoid outcome is associated with CXCL10-induced matrix metalloproteinase 9 secretion from monocytes and neutrophils but not lymphocytes","volume":"139","author":"Riani","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B285","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01972","article-title":"IL-23\/IL-17 axis activates IL-1\u03b2-associated inflammasome in macrophages and generates an auto-inflammatory response in a subgroup of patients with bullous pemphigoid","volume":"10","author":"Le Jan","year":"2019","journal-title":"Front Immunol"},{"key":"B286","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-012-9828-3","article-title":"Glucocorticoid receptor-beta up-regulation and steroid resistance induction by IL-17 and IL-23 cytokine stimulation in peripheral mononuclear cells","volume":"33","author":"Vazquez-Tello","year":"2013","journal-title":"J Clin Immunol"},{"key":"B287","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16559","article-title":"Ixekizumab successfully treated refractory psoriasis concurrent bullous pemphigoid","volume":"50","author":"Xiao","year":"2023","journal-title":"J Dermatol"},{"key":"B288","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.2017.31.issue-5","article-title":"A successful treatment with ustekinumab in a case of relapsing bullous pemphigoid associated with psoriasis","volume":"31","author":"Loget","year":"2017","journal-title":"J Eur Acad Dermatol Venereology: JEADV"},{"key":"B289","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1171802","article-title":"Development of bullous pemphigoid during treatment of psoriasis with ustekinumab: a case report and literature review","volume":"10","author":"Kong","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"B290","doi-asserted-by":"publisher","first-page":"e15207","DOI":"10.1111\/dth.15207","article-title":"Guselkumab-associated bullous pemphigoid in a psoriasis patient: A case report and review of the literature","volume":"35","author":"Burlando","year":"2022","journal-title":"Dermatol Ther"},{"key":"B291","doi-asserted-by":"publisher","first-page":"2366535","DOI":"10.1080\/09546634.2024.2366535","article-title":"A case report of bullous pemphigoid following secukinumab therapy for a patient with psoriasis","volume":"35","author":"Wang","year":"2024","journal-title":"J Dermatolog Treat"},{"key":"B292","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2021.04.006","article-title":"Cytokine-skewed Tfh cells: functional consequences for B cell help","volume":"42","author":"Olatunde","year":"2021","journal-title":"Trends Immunol"},{"key":"B293","doi-asserted-by":"publisher","first-page":"e68145","DOI":"10.1371\/journal.pone.0068145","article-title":"Follicular helper T Cells (Tfh) and IL-21 involvement in the pathogenesis of bullous pemphigoid","volume":"8","author":"Li","year":"2013","journal-title":"PloS One"},{"key":"B294","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15713","article-title":"Possible roles of CXCL13\/CXCR5 axis in the development of bullous pemphigoid","volume":"48","author":"Ohuchi","year":"2021","journal-title":"J Dermatol"},{"key":"B295","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.03.014","article-title":"Regulatory T-cell dysfunction induces autoantibodies to bullous pemphigoid antigens in mice and human subjects","volume":"142","author":"Muramatsu","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B296","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.2014.28.issue-2","article-title":"Regulatory T cells in skin lesions and blood of patients with bullous pemphigoid","volume":"28","author":"Antiga","year":"2014","journal-title":"J Eur Acad Dermatol Venereology: JEADV"},{"key":"B297","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-012-1213-9","article-title":"Circulating CD4+ CD25brightFOXP3+ regulatory T-cells are significantly reduced in bullous pemphigoid patients","volume":"304","author":"Quaglino","year":"2012","journal-title":"Arch Dermatol Res"},{"key":"B298","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/j.1600-0625.2006.00522.x","article-title":"Frequency, function and CLA expression of CD4+CD25+FOXP3+ regulatory T cells in bullous pemphigoid","volume":"16","author":"Rensing-Ehl","year":"2007","journal-title":"Exp Dermatol"},{"key":"B299","doi-asserted-by":"publisher","DOI":"10.1006\/cyto.1999.0642","article-title":"Presence of interleukin 10 in the serum and blister fluid of patients with pemphigus vulgaris and pemphigoid","volume":"12","author":"Bhol","year":"2000","journal-title":"Cytokine"},{"key":"B300","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.04.006","article-title":"Regulatory T-cell deficiency leads to pathogenic bullous pemphigoid antigen 230 autoantibody and autoimmune bullous disease","volume":"142","author":"Haeberle","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B301","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2018.09.002","article-title":"IL-6: a cytokine at the crossroads of autoimmunity","volume":"55","author":"Jones","year":"2018","journal-title":"Curr Opin Immunol"},{"key":"B302","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.3390\/ijms22052719","article-title":"The role of tumor necrosis factor alpha (TNF-\u03b1) in autoimmune disease and current TNF-\u03b1 Inhibitors in therapeutics","volume":"22","author":"Jang","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B303","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1190388","article-title":"Aberrant inflammasome activation as a driving force of human autoimmune skin disease","volume":"14","author":"Fetter","year":"2023","journal-title":"Front Immunol"},{"key":"B304","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.10.055","article-title":"Treatment of coexisting bullous pemphigoid and psoriasis with the tumor necrosis factor antagonist etanercept","volume":"54","author":"Yamauchi","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"B305","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2012.01659.x","article-title":"Case of coexisting psoriatic arthritis and bullous pemphigoid improved by etanercept","volume":"40","author":"Nin","year":"2013","journal-title":"J Dermatol"},{"key":"B306","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2022.2089331","article-title":"Bullous pemphigoid induced by biologic drugs in psoriasis: a systematic review","volume":"33","author":"Husein-ElAhmed","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"B307","doi-asserted-by":"publisher","first-page":"6716419","DOI":"10.1155\/2017\/6716419","article-title":"Expression of the JAK\/STAT signaling pathway in bullous pemphigoid and dermatitis herpetiformis","volume":"2017","author":"Juczynska","year":"2017","journal-title":"Mediators Inflammation"},{"key":"B308","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1464474","article-title":"Treatment and molecular analysis of bullous pemphigoid with tofacitinib: a case report and review of current literature","volume":"15","author":"Li X","year":"2024","journal-title":"Front Immunol"},{"key":"B309","doi-asserted-by":"publisher","DOI":"10.1111\/dth.v35.10","article-title":"Concurrent bullous pemphigoid and plaque psoriasis successfully treated with Janus kinase inhibitor Baricitinib","volume":"35","author":"Xiao","year":"2022","journal-title":"Dermatol Ther"},{"key":"B310","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jdcr.2022.10.028","article-title":"Two cases of bullous pemphigoid effectively treated with oral tofacitinib","volume":"32","author":"Youssef","year":"2023","journal-title":"JAAD Case Rep"},{"key":"B311","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2022.12.006","article-title":"Bullous pemphigoid treated with Janus kinase inhibitor upadacitinib","volume":"32","author":"Nash","year":"2023","journal-title":"JAAD Case Rep"},{"key":"B312","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljac078","article-title":"Tofacitinib in recalcitrant bullous pemphigoid: a report of seven cases","volume":"188","author":"Fan","year":"2023","journal-title":"Br J Dermatol"},{"key":"B313","doi-asserted-by":"publisher","first-page":"2050313X231160926","DOI":"10.1177\/2050313X231160926","article-title":"A case of drug-induced bullous pemphigoid secondary to immunotherapy treated with upadacitinib: A case report","volume":"11","author":"Gresham","year":"2023","journal-title":"SAGE Open Med Case Rep"},{"key":"B314","doi-asserted-by":"publisher","first-page":"110591","DOI":"10.1016\/j.intimp.2023.110591","article-title":"Concurrent bullous pemphigoid and psoriasis vulgaris successfully treated with Janus kinase inhibitor tofacitinib: A case report and review of the literature","volume":"122","author":"Li","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B315","article-title":"Highly selective JAK1 inhibitor for the treatment of refractory bullous pemphigoid: a case report","volume":"39","author":"Sun","year":"2023","journal-title":"China J Leprosy Skin Dis"},{"key":"B316","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19475","article-title":"Abrocitinib-A promising option for patients with refractory bullous pemphigoid","volume":"38","author":"Jiang","year":"2024","journal-title":"J Eur Acad Dermatol Venereology: JEADV"},{"key":"B317","doi-asserted-by":"publisher","first-page":"2302394","DOI":"10.1080\/09546634.2024.2302394","article-title":"Upadacitinib for the management of bullous pemphigoid coexisting with psoriasis vulgaris: a case report and literature review","volume":"35","author":"Su","year":"2024","journal-title":"J Dermatolog Treat"},{"key":"B318","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.171361","article-title":"Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment","volume":"46","author":"Smolen","year":"2019","journal-title":"J Rheumatol"},{"key":"B319","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002735","article-title":"Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis","volume":"9","author":"Burmester","year":"2023","journal-title":"RMD Open"},{"key":"B320","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1136\/annrheumdis-2021-221915","article-title":"Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study","volume":"81","author":"Khosrow-Khavar","year":"2022","journal-title":"Ann Rheumatic Dis"},{"key":"B321","doi-asserted-by":"publisher","DOI":"10.1002\/art.42250","article-title":"Tofacitinib and risk of Malignancy: results from the safety of tofacitinib in routine care patients with rheumatoid arthritis (STAR-RA) study","volume":"74","author":"Khosrow-Khavar","year":"2022","journal-title":"Arthritis Rheumatol (Hoboken N.J.)"},{"key":"B322","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-223916","article-title":"Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme","volume":"82","author":"Fleischmann","year":"2023","journal-title":"Ann Rheumatic Dis"},{"key":"B323","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224049","article-title":"JAK inhibitors and the risk of Malignancy: a meta-analysis across disease indications","volume":"82","author":"Russell","year":"2023","journal-title":"Ann Rheumatic Dis"},{"key":"B324","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001395","article-title":"Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme","volume":"6","author":"Cohen","year":"2020","journal-title":"RMD Open"},{"key":"B325","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221276","article-title":"Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database","volume":"81","author":"Taylor","year":"2022","journal-title":"Ann Rheumatic Dis"},{"key":"B326","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218510","article-title":"Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme","volume":"80","author":"Cohen","year":"2021","journal-title":"Ann Rheumatic Dis"},{"key":"B327","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221051","article-title":"Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years","volume":"81","author":"Winthrop","year":"2022","journal-title":"Ann Rheumatic Dis"},{"key":"B328","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"New Engl J Med"},{"key":"B329","unstructured":"FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions\n          \n          \n          \n          2021"},{"key":"B330","unstructured":"EMA recommends measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders\n          \n          \n          \n          2022"},{"key":"B331","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222259","article-title":"Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance","volume":"82","author":"Charles-Schoeman","year":"2023","journal-title":"Ann Rheumatic Dis"},{"key":"B332","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222543","article-title":"Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial","volume":"82","author":"Curtis","year":"2023","journal-title":"Ann Rheumatic Dis"},{"key":"B333","doi-asserted-by":"publisher","DOI":"10.1002\/art.42846","article-title":"Risk of venous thromboembolism with tofacitinib versus tumor necrosis factor inhibitors in cardiovascular risk-enriched rheumatoid arthritis patients","volume":"76","author":"Charles-Schoeman","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"B334","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222405","article-title":"Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial","volume":"81","author":"Balanescu","year":"2022","journal-title":"Ann Rheumatic Dis"},{"key":"B335","doi-asserted-by":"publisher","first-page":"1759720X231201047","DOI":"10.1177\/1759720X231201047","article-title":"Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: a post hoc analysis of ORAL Surveillance","volume":"15","author":"Karpouzas","year":"2023","journal-title":"Ther Adv Musculoskeletal Dis"},{"key":"B336","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223715","article-title":"Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance","volume":"82","author":"Kristensen","year":"2023","journal-title":"Ann Rheumatic Dis"},{"key":"B337","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","article-title":"EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update","volume":"76","author":"Agca","year":"2017","journal-title":"Ann Rheumatic Dis"},{"key":"B338","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(96)00210-9","article-title":"Rheumatoid arthritis and cancer risk","author":"Mellemkjaer","year":"1996","journal-title":"Eur J Cancer"},{"key":"B339","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-017-3844-9","article-title":"Tofacitinib improves atherosclerosis despite up-regulating serum cholesterol in patients with active rheumatoid arthritis: a cohort study","volume":"37","author":"Kume","year":"2017","journal-title":"Rheumatol Int"},{"key":"B340","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001804","article-title":"Prospective, simultaneous assessment of joint and vascular inflammation by PET\/CT in tofacitinib-treated patients with rheumatoid arthritis: associations with vascular and bone status","volume":"7","author":"Hamar","year":"2021","journal-title":"RMD Open"},{"key":"B341","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206624","article-title":"The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"74","author":"Roubille","year":"2015","journal-title":"Ann Rheumatic Dis"},{"key":"B342","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljac059","article-title":"Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials","volume":"188","author":"King","year":"2023","journal-title":"Br J Dermatol"},{"key":"B343","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-022-00701-3","article-title":"JAK in the [Black] box: A dermatology perspective on systemic JAK inhibitor safety","volume":"23","author":"Elmariah","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"B344","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.v36.11","article-title":"The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis - A network meta-analysis","volume":"36","author":"Zhang","year":"2022","journal-title":"J Eur Acad Dermatol Venereology: JEADV"},{"key":"B345","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-024-00869-w","article-title":"Integrated safety update of abrocitinib in 3802 patients with moderate-to-severe atopic dermatitis: data from more than 5200 patient-years with up to 4 years of exposure","volume":"25","author":"Simpson","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"B346","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.547","article-title":"Malignancies in pemphigus and pemphigoid diseases","volume":"135","author":"Schulze","year":"2015","journal-title":"J Invest Dermatol"},{"key":"B347","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.029740","article-title":"Risk of incident venous thromboembolism among patients with bullous pemphigoid or pemphigus vulgaris: A nationwide cohort study with meta-analysis","volume":"12","author":"Chen","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"B348","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jaad.2024.02.052","article-title":"Autoimmune blistering disorders and cardiovascular risks: A population-based cohort study","volume":"91","author":"Bonnesen","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"B349","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/annrheumdis-2020-218398","article-title":"Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement","volume":"80","author":"Nash","year":"2021","journal-title":"Ann Rheumatic Dis"},{"key":"B350","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.7b01598","article-title":"Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A selective JAK1 clinical candidate for the treatment of autoimmune diseases","volume":"61","author":"Vazquez","year":"2018","journal-title":"J Med Chem"},{"key":"B351","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-318448","article-title":"JAK selectivity for inflammatory bowel disease treatment: does it clinically matter","volume":"68","author":"Danese","year":"2019","journal-title":"Gut"},{"key":"B352","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s41927-018-0031-x","article-title":"In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)","volume":"2","author":"Parmentier","year":"2018","journal-title":"BMC Rheumatol"},{"key":"B353","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.v7.6","article-title":"Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition","volume":"7","author":"Dowty","year":"2019","journal-title":"Pharmacol Res Perspect"},{"key":"B354","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s13075-019-1964-1","article-title":"Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations","volume":"21","author":"McInnes","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"B355","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219012","article-title":"JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib","volume":"80","author":"Traves","year":"2021","journal-title":"Ann Rheumatic Dis"},{"key":"B356","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1610253113","article-title":"Network pharmacology of JAK inhibitors","volume":"113","author":"Moodley","year":"2016","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B357","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"van Vollenhoven","year":"2012","journal-title":"New Engl J Med"},{"key":"B358","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"New Engl J Med"},{"key":"B359","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.08.009","article-title":"JAK inhibitors in the treatment of atopic dermatitis","volume":"148","author":"Chovatiya","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B360","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.05.049","article-title":"Janus kinase inhibitors for alopecia areata","volume":"89","author":"King","year":"2023","journal-title":"J Am Acad Dermatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1563286\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T02:04:02Z","timestamp":1744077842000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1563286\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,8]]},"references-count":360,"alternative-id":["10.3389\/fimmu.2025.1563286"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1563286","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,8]]},"article-number":"1563286"}}